BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 32118427)

  • 1. Discovery of Acylsulfonohydrazide-Derived Inhibitors of the Lysine Acetyltransferase, KAT6A, as Potent Senescence-Inducing Anti-Cancer Agents.
    Priebbenow DL; Leaver DJ; Nguyen N; Cleary B; Lagiakos HR; Sanchez J; Xue L; Huang F; Sun Y; Mujumdar P; Mudududdla R; Varghese S; Teguh S; Charman SA; White KL; Shackleford DM; Katneni K; Cuellar M; Strasser JM; Dahlin JL; Walters MA; Street IP; Monahan BJ; Jarman KE; Jousset Sabroux H; Falk H; Chung MC; Hermans SJ; Downer NL; Parker MW; Voss AK; Thomas T; Baell JB
    J Med Chem; 2020 May; 63(9):4655-4684. PubMed ID: 32118427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Benzoylsulfonohydrazides as Potent Inhibitors of the Histone Acetyltransferase KAT6A.
    Leaver DJ; Cleary B; Nguyen N; Priebbenow DL; Lagiakos HR; Sanchez J; Xue L; Huang F; Sun Y; Mujumdar P; Mudududdla R; Varghese S; Teguh S; Charman SA; White KL; Katneni K; Cuellar M; Strasser JM; Dahlin JL; Walters MA; Street IP; Monahan BJ; Jarman KE; Sabroux HJ; Falk H; Chung MC; Hermans SJ; Parker MW; Thomas T; Baell JB
    J Med Chem; 2019 Aug; 62(15):7146-7159. PubMed ID: 31256587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.
    Baell JB; Leaver DJ; Hermans SJ; Kelly GL; Brennan MS; Downer NL; Nguyen N; Wichmann J; McRae HM; Yang Y; Cleary B; Lagiakos HR; Mieruszynski S; Pacini G; Vanyai HK; Bergamasco MI; May RE; Davey BK; Morgan KJ; Sealey AJ; Wang B; Zamudio N; Wilcox S; Garnham AL; Sheikh BN; Aubrey BJ; Doggett K; Chung MC; de Silva M; Bentley J; Pilling P; Hattarki M; Dolezal O; Dennis ML; Falk H; Ren B; Charman SA; White KL; Rautela J; Newbold A; Hawkins ED; Johnstone RW; Huntington ND; Peat TS; Heath JK; Strasser A; Parker MW; Smyth GK; Street IP; Monahan BJ; Voss AK; Thomas T
    Nature; 2018 Aug; 560(7717):253-257. PubMed ID: 30069049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel inhibitors of histone acetyltransferase hMOF through high throughput screening.
    Zhang R; Wang J; Zhao L; Liu S; Du D; Ding H; Chen S; Yue L; Liu YC; Zhang C; Liu H; Luo C
    Eur J Med Chem; 2018 Sep; 157():867-876. PubMed ID: 30145373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido)benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs.
    Li XY; Liang JW; Mohamed O K; Zhang TJ; Lu GQ; Meng FH
    Eur J Med Chem; 2018 Jun; 154():267-279. PubMed ID: 29807332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors.
    Yang Y; Zhang R; Li Z; Mei L; Wan S; Ding H; Chen Z; Xing J; Feng H; Han J; Jiang H; Zheng M; Luo C; Zhou B
    J Med Chem; 2020 Feb; 63(3):1337-1360. PubMed ID: 31910017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression.
    Becker OM; Dhanoa DS; Marantz Y; Chen D; Shacham S; Cheruku S; Heifetz A; Mohanty P; Fichman M; Sharadendu A; Nudelman R; Kauffman M; Noiman S
    J Med Chem; 2006 Jun; 49(11):3116-35. PubMed ID: 16722631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of N-(2-oxoethyl) sulfanilamide-derived inhibitors of KAT6A (MOZ) against leukemia by an isostere strategy.
    Duan Y; Zhao Y; Li Z; Liu Z; Wang M; Wang X; Sun M; Song C; Yao Y
    Eur J Med Chem; 2023 Nov; 260():115770. PubMed ID: 37651878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activities.
    Lu T; Goh AW; Yu M; Adams J; Lam F; Teo T; Li P; Noll B; Zhong L; Diab S; Chahrour O; Hu A; Abbas AY; Liu X; Huang S; Sumby CJ; Milne R; Midgley C; Wang S
    J Med Chem; 2014 Mar; 57(6):2275-91. PubMed ID: 24471873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of N-(4'-(indol-2-yl)phenyl)sulfonamides as novel inhibitors of HCV replication.
    Chen G; Ren H; Turpoff A; Arefolov A; Wilde R; Takasugi J; Khan A; Almstead N; Gu Z; Komatsu T; Freund C; Breslin J; Colacino J; Hedrick J; Weetall M; Karp GM
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3942-6. PubMed ID: 23683596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity.
    Ott GR; Wells GJ; Thieu TV; Quail MR; Lisko JG; Mesaros EF; Gingrich DE; Ghose AK; Wan W; Lu L; Cheng M; Albom MS; Angeles TS; Huang Z; Aimone LD; Ator MA; Ruggeri BA; Dorsey BD
    J Med Chem; 2011 Sep; 54(18):6328-41. PubMed ID: 21859094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-Hydrazinoisatin-based benzenesulfonamides as novel carbonic anhydrase inhibitors endowed with anticancer activity: Synthesis, in vitro biological evaluation and in silico insights.
    Abo-Ashour MF; Eldehna WM; Nocentini A; Bonardi A; Bua S; Ibrahim HS; Elaasser MM; Kryštof V; Jorda R; Gratteri P; Abou-Seri SM; Supuran CT
    Eur J Med Chem; 2019 Dec; 184():111768. PubMed ID: 31629164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of hydrazino and hydrazido linkers to connect benzenesulfonamides with hydrophilic/phobic tails for targeting the middle region of human carbonic anhydrases active site: Selective inhibitors of hCA IX.
    Allam HA; Fahim SH; F Abo-Ashour M; Nocentini A; Elbakry ME; Abdelrahman MA; Eldehna WM; Ibrahim HS; Supuran CT
    Eur J Med Chem; 2019 Oct; 179():547-556. PubMed ID: 31276899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Action plan for hit identification (APHID): KAT6A as a case study.
    Yi X; Xue L; Thomas T; Baell JB
    Future Med Chem; 2020 Mar; 12(5):423-437. PubMed ID: 32064938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Histone Acetyltransferase MOZ/KAT6A as a New Avenue for Hematological Tumor Therapy.
    Zhou C; Zhu HL; Duan Y
    Curr Top Med Chem; 2020; 20(5):333-335. PubMed ID: 32242512
    [No Abstract]   [Full Text] [Related]  

  • 16. Design, synthesis and evaluation of novel polypharmacological antichlamydial agents.
    Sunduru N; Salin O; Gylfe Å; Elofsson M
    Eur J Med Chem; 2015 Aug; 101():595-603. PubMed ID: 26204507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B.
    Zhang X; Zhang N; Chen G; Turpoff A; Ren H; Takasugi J; Morrill C; Zhu J; Li C; Lennox W; Paget S; Liu Y; Almstead N; Njoroge FG; Gu Z; Komatsu T; Clausen V; Espiritu C; Graci J; Colacino J; Lahser F; Risher N; Weetall M; Nomeir A; Karp GM
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3947-53. PubMed ID: 23683597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.
    Quattropani A; Dorbais J; Covini D; Pittet PA; Colovray V; Thomas RJ; Coxhead R; Halazy S; Scheer A; Missotten M; Ayala G; Bradshaw C; De Raemy-Schenk AM; Nichols A; Cirillo R; Tos EG; Giachetti C; Golzio L; Marinelli P; Church DJ; Barberis C; Chollet A; Schwarz MK
    J Med Chem; 2005 Dec; 48(24):7882-905. PubMed ID: 16302826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.
    D'Angelo ND; Kim TS; Andrews K; Booker SK; Caenepeel S; Chen K; D'Amico D; Freeman D; Jiang J; Liu L; McCarter JD; San Miguel T; Mullady EL; Schrag M; Subramanian R; Tang J; Wahl RC; Wang L; Whittington DA; Wu T; Xi N; Xu Y; Yakowec P; Yang K; Zalameda LP; Zhang N; Hughes P; Norman MH
    J Med Chem; 2011 Mar; 54(6):1789-811. PubMed ID: 21332118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
    Sharma S; Chung CY; Uryu S; Petrovic J; Cao J; Rickard A; Nady N; Greasley S; Johnson E; Brodsky O; Khan S; Wang H; Wang Z; Zhang Y; Tsaparikos K; Chen L; Mazurek A; Lapek J; Kung PP; Sutton S; Richardson PF; Greenwald EC; Yamazaki S; Jones R; Maegley KA; Bingham P; Lam H; Stupple AE; Kamal A; Chueh A; Cuzzupe A; Morrow BJ; Ren B; Carrasco-Pozo C; Tan CW; Bhuva DD; Allan E; Surgenor E; Vaillant F; Pehlivanoglu H; Falk H; Whittle JR; Newman J; Cursons J; Doherty JP; White KL; MacPherson L; Devlin M; Dennis ML; Hattarki MK; De Silva M; Camerino MA; Butler MS; Dolezal O; Pilling P; Foitzik R; Stupple PA; Lagiakos HR; Walker SR; Hediyeh-Zadeh S; Nuttall S; Spall SK; Charman SA; Connor T; Peat TS; Avery VM; Bozikis YE; Yang Y; Zhang M; Monahan BJ; Voss AK; Thomas T; Street IP; Dawson SJ; Dawson MA; Lindeman GJ; Davis MJ; Visvader JE; Paul TA
    Cell Chem Biol; 2023 Oct; 30(10):1191-1210.e20. PubMed ID: 37557181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.